RxDoctor Payments DataLook up a doctor →

Matthew Finneran, MD

Family Medicine · Wadsworth, OHNPI 1659341030

Payments from drug & device makers

$346,370in general payments, 2019–2025

Across 993 payments — averaging $348.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$295K
  • AbbVie$28K
  • GSK$24K
  • Novo Nordisk$220
  • Bayer$139
  • Amgen$81
  • plus $299 from 10 others
$1,461in research payments, 2019–2025

Across 12 payments — averaging $121.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$1K

What the payments were for

  • Food & beverage$818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$346,370 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$115,096
Medicare patients
244
Services billed
2,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$98,910
EliquisApixaban71$91,995
RybelsusSemaglutide35$47,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$40,921
XareltoRivaroxaban30$33,755
JanuviaSitagliptin Phosphate26$29,429
OzempicSemaglutide16$21,854
FarxigaDapagliflozin Propanediol17$20,743
JanumetSitagliptin Phos/Metformin Hcl15$18,538
TradjentaLinagliptin22$17,813
Breo ElliptaFluticasone/Vilanterol18$14,104
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,141
Spiriva HandihalerTiotropium Bromide11$5,356
OxycontinOxycodone Hcl11$5,099
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$91,99571 claims
Novo NordiskRybelsus, Ozempic$220$69,77751 claims
GSKTrelegy Ellipta, Breo Ellipta$23,592$55,02446 claims
MerckJanuvia, Janumet$17$47,96741 claims
AstraZenecaFarxiga$69$20,74317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Wadsworth

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →